SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OXIGENE INC. (OXGN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (232)8/17/2001 9:35:39 PM
From: Miljenko Zuanic  Read Replies (1) of 273
 
WE,

OXGN was (and in small part still is, not counting one which I can not talk about) my worst performing holding in last two years.

After first rumor appearance, and based on my own DD, I sold ~80% before going in vocation in Croatia.

First cautious flag was in Dec. 00, when BMS announce that they are REPEATING PI trials (IND news). Second was when I was unable to identify trial on net. Rumor was third red flag.
That drug may have trombotic and cardiovascular side effects is nothing new. However, that this events are again problems at the reduced doses (>70 mg/m^2) is very troublesome.

I contacted OXGN (CEP) by e-mail several times asking info about trials status but never got respond. In my rating OXGN management is one of the worst that I know. Actually they STINK very much, and if this is going to court I will participate.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News